论文部分内容阅读
美国ＦＤＡ抗病毒药顾问委员会已一致推荐批准默克公司的每天 1次静脉注射抗真菌药ｃａｓｐｏｆｕｎ ｇｉｎ(ｃａｎｃｉｄａｓ) ,用于治疗顽固性或不能耐受其他治疗的侵入性曲霉病患者。如果获准 ,ｃａｓｐｏｆｕｎｇｉｎ将是这种抗真菌药物棘球白素类 (ｅｃｈｉｎｏｃａｄｉｎ
The FDA Antiviral Advisor Council has unanimously recommended the approval of Merck’s once daily intravenous antifungal caspofun gin (cancidas) for patients with invasive aspergillosis who are refractory or unable to tolerate other treatments. If approved, caspofungin will be the antifungal drug echinocadin